Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04B UROLOGICALS
G04BE Drugs used in erectile dysfunction
G04BE09 Vardenafil
D03260 Vardenafil hydrochloride hydrate (JAN) <JP/US>
USP drug classification [BR:br08302]
Sexual Disorder Agents
Sexual Disorder Agents (Male)
Vardenafil
D03260 Vardenafil hydrochloride hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
25 Urogenital and anal organ agents
259 Miscellaneous
2590 Miscellaneous
D03260 Vardenafil hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01509 Phosphodiesterase V inhibitor
DG00487 Vardenafil
D03260 Vardenafil hydrochloride hydrate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00487 Vardenafil
D03260 Vardenafil hydrochloride hydrate
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Phosphodiesterases
PDE5
D03260 Vardenafil hydrochloride hydrate (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03260
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03260
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03260
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03260
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03260
Drug groups [BR:br08330]
Cardiovascular agent
DG01509 Phosphodiesterase V inhibitor
DG00487 Vardenafil
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00487 Vardenafil